Xenetic Biosciences Stock Today
| XBIO Stock | USD 4.20 0.09 2.19% |
Performance2 of 100
| Odds Of DistressOver 81
|
Xenetic Biosciences is selling at 4.20 as of the 28th of November 2024; that is 2.19 percent increase since the beginning of the trading day. The stock's open price was 4.11. Xenetic Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Xenetic Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of September 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of June 2014 | Category Healthcare | Classification Health Care |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell platform technology engineered to target patient-specific tumor neoantigens. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts. The company has 1.54 M outstanding shares of which 14.83 K shares are at this time shorted by private and institutional investors with about 0.77 trading days to cover. More on Xenetic Biosciences
Moving against Xenetic Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Xenetic Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Director | Jeffrey Esq | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsXenetic Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Xenetic Biosciences' financial leverage. It provides some insight into what part of Xenetic Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Xenetic Biosciences (XBIO) is traded on NASDAQ Exchange in USA. It is located in 945 Concord Street, Framingham, MA, United States, 01701 and employs 4 people. Xenetic Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.34 M. Xenetic Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.54 M outstanding shares of which 14.83 K shares are at this time shorted by private and institutional investors with about 0.77 trading days to cover.
Xenetic Biosciences currently holds about 14.93 M in cash with (4.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04.
Check Xenetic Biosciences Probability Of Bankruptcy
Ownership AllocationXenetic Biosciences maintains 19.05 (%) of its outstanding shares held by insiders and 2.09 (%) owned by institutional investors.
Check Xenetic Ownership Details
Xenetic Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Sachetta Llc | 2024-09-30 | 17.4 K | |
| Renaissance Technologies Corp | 2024-09-30 | 15.8 K | |
| Geode Capital Management, Llc | 2024-09-30 | 11.9 K | |
| Jtc Employer Solutions Trustee Ltd | 2024-09-30 | 2.7 K | |
| Ubs Group Ag | 2024-06-30 | 182 | |
| Bank Of America Corp | 2024-06-30 | 11.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.0 | |
| Harwood Advisory Group, Llc | 2024-09-30 | 2.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Tower Research Capital Llc | 2024-06-30 | 0.0 | |
| Steward Partners Investment Advisory, Llc | 2024-06-30 | 0.0 |
Xenetic Biosciences Historical Income Statement
Xenetic Stock Against Markets
Xenetic Biosciences Corporate Executives
Elected by the shareholders, the Xenetic Biosciences' board of directors comprises two types of representatives: Xenetic Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xenetic. The board's role is to monitor Xenetic Biosciences' management team and ensure that shareholders' interests are well served. Xenetic Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xenetic Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Parslow | CFO, Principal Accounting Officer, Principal Financial Officer | Profile |
Already Invested in Xenetic Biosciences?
The danger of trading Xenetic Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Xenetic Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Xenetic Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Xenetic Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Xenetic Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Xenetic Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xenetic Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xenetic Biosciences Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Revenue Per Share 1.638 | Quarterly Revenue Growth 0.116 | Return On Assets (0.29) | Return On Equity (0.49) |
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.